• Small Molecules
    • Large Molecules
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Scientific Posters

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

In silico toxicity prediction using Derek Nexus for predicting skin sensitization, phototoxicity, hepatotoxicity and in vitro hERG inhib

In silico toxicity evaluation using Derek® Nexus for quicker and cost-effective screening for skin sensitization phototoxicity, hepatotoxicity, and in vitro hERG channel inhibition


Chromatography based purification of retro virus spikes

Presenting the data for purification of Retro virus using ion exchange chromatography where the condition for purification was optimized.

Early discovery due diligence of immuno target through multi pronged approaches

Our approach to informed decision-making during early discovery stage to create novel, best-in-class drugs.

Effect of Container Closure Systems on Stability of Pharmaceutical Products

Case studies on how Syngene handled unique problems in Stability Testing arising from packaging material.

Efficient Scale Up of Therapeutic Antibody Manufacturing Processes

Syngene’s ‘first-time-right’ Technology Transfer approach to achieve timely clinical and commercial milestones.

Mechanistic insights into drug-drug interactions from large-scale toxicogenomics data

How to manage the risk of drug-drug interactions in drug development and during poly therapy especially with elderly patients.

Profiling CEACAM7 as a potential target for pancreatic cancer

Demonstrating the therapeutic edge of targeting CEACAM7 in pancreatic cancer using an integrative approach between biology and bioinformatics.

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To download, Please share your details

To download, Please share your details